Comparative Pharmacology
Head-to-head clinical analysis: PENCICLOVIR versus XOFLUZA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PENCICLOVIR versus XOFLUZA.
PENCICLOVIR vs XOFLUZA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Penciclovir is a nucleoside analog that inhibits viral DNA polymerase. It is phosphorylated by viral thymidine kinase to penciclovir triphosphate, which competitively inhibits viral DNA polymerase and terminates DNA chain elongation.
Baloxavir marboxil is a prodrug that is converted to baloxavir acid, which inhibits the cap-dependent endonuclease activity of the influenza virus polymerase acidic protein, thereby preventing viral mRNA transcription and replication.
Topical: Apply 1% cream every 2 hours while awake (approximately 9 times/day) for 4 days. Oral: 500 mg twice daily for 5 days.
40 mg orally once as a single dose; for patients weighing ≥80 kg, 80 mg orally once as a single dose.
None Documented
None Documented
Terminal half-life: 2.0–2.5 hours (healthy adults); prolonged to ~9–10 hours in renal impairment (CrCl <30 mL/min); clinical context: dosing interval adjusted based on renal function.
The terminal elimination half-life of baloxavir marboxil is approximately 79.1 hours (range 53–107 hours), supporting single-dose therapy for influenza.
Renal excretion: >70% as unchanged penciclovir via glomerular filtration and tubular secretion.
Baloxavir marboxil is primarily excreted via feces (80.1%) and urine (14.7%) after oral administration, with <1% as unchanged drug in urine.
Category A/B
Category C
Antiviral
Antiviral